刘建平

1982年毕业于中国药科大学药学专业,现为中国药科大学药剂研究所所长、药剂教研室副主任,药剂学博士、教授、博士生导师。1999年赴新西兰Otago大学药学院进修。
  兼任国家食品药品监督管理局保健品审评专家、农业部兽药审评专家、江苏省药剂专业委员会副主任、江苏省药品保健品制剂审评专家、江苏省九三学社医药委员会委员等职。
研究方向:生物功能性药物载体,缓控释制剂、经皮给药系统、中药新剂型
主要研究内容和成果:利用血浆高密度脂蛋白逆转运胆固醇,具有抗动脉粥样硬化的性质和作用,重组高密度脂蛋白载药系统,达到载体与药物的协同治疗作用,获2项国家自然科学基金项目资助;针对中药多成分体内过程差异较大,不利于发挥协同作用的问题,对中药多成分体内过程进行药动学与药效学的二次调控与改造,获1项国家自然科学基金项目资助。主持科技部“十一五”重大专项、国家中医药管理局项目、江苏省“六大人才”高峰项目、江苏省自然科学基金、江苏省社会发展基金等项目项目,负责或参与科技部“十五”国家科技攻关、“十一五”国家科技支撑计划、新西兰国际合作项目、江苏省高新技术招标项目、江苏省科技基础设施建设计划-科技公共服务平台项目、江苏省中医药管理局项目以及企业合作开发项目等共25项。
   通过江苏省科技厅成果鉴定三项,获2004年南京市科技进步奖三等奖、2011国家人口和计生委优秀科技成果一等奖,申请发明专利27项,已授权9项。发表论文129篇(其中SCI 42篇、EI收载2篇)。
近3年发表的代表性论文(以下均为通讯作者)
  1. Post-insertion of poloxamer 188 strengthened liposomal membrane and reduced drug irritancy and in vivo precipitation, superior to PEGylation [J]. Journal of Controlled Release, 2015, 23(10): 161-169.(SCI,7.705)
  2. Suppression of Remodeling Behaviors with Arachidonic Acid Modification for Enhanced in vivo Antiatherogenic Efficacies of Lovastatin-loaded Discoidal Recombinant High Density Lipoprotein[J]. Pharmaceutical Research, Published online:04 June 2015.(SCI,3.952)
  3. Tanshinone IIA loaded pellets developed for angina chronotherapy: Deconvolution-based formulation design and optimization, pharmacokinetic and pharmacodynamic evaluation[J]. European Journal of Pharmaceutical Sciences, 2015, 76(2015): 156–164.(SCI,3.35)
  4. Strategies to Maximize Liposomal Drug Loading for a Poorly Water-soluble Anticancer Drug [J]. Pharmaceutical research, 2015, 32(4): 1451-1461. (SCI,3.952)
  5. Physicochemical characterization of asulacrine towards the development of an anticancer liposomal formulation via active drug loading: Stability, solubility, lipophilicity and ionization. International Journal of Pharmaceutics, 2014, 473 (1–2), 528–535. (SCI,3.785)
  6. Hyaluronic acid-decorated reconstitude high density lipoprotein targeting atherosclerotic lesion [J]. Biomaterials, 2014, 35(27): 8002–8014. (SCI,8.312)
  7. Arachidonic Acid-modified Lovastatin Discoidal Reconstituted High Density Lipoprotein Markedly Decrease the Drug Leakage during the Remodeling Behaviors Induced by Lecithin Cholesterol  Acyltransferase. Pharmaceutical Research, 2014, 31(7): 1689-1709. ( SCI, 3.952)
  8. Pharmacokinetics and atherosclerotic lesions targeting effects of tanshinone IIA discoidal and spherical biomimetic high density lipoproteins, Biomaterials, 2013, 34(1):306-319. (SCI, 7.604)
  9. Bioavailability and foam cells permeability enhancement of Salvianolic acid B pellets based on drug–phospholipids complex technique. European journal of pharmaceutics and biopharmaceutics, 2013,83(1):76-86. (SCI,3.826)
  10. Release Behavior of Tanshinone IIA Sustained-Release Pellets Based on Crack Formation Theory. Journal of pharmaceutical sciences, 2012,101(8):2811-2820. (SCI,3.055)
  11. Preparation, Characterizations, and In Vitro Metabolic Processes of Paclitaxel-Loaded Discoidal Recombinant High-Density Lipoproteins. Journal of pharmaceutical science, 2012,101(8):2900-2908. (SCI,3.055)
  12. Novel Tanshinone II A ternary solid dispersion pellets prepared by a single-step technique: in vitro and in vivo evaluation. European Journal of Pharmaceutics and Biopharmaceutics, 2012,80:426-432. (SCI,4.269) 
联系方式:025-83271293(O), 13951923397, jianpingliu1293@163.com